The Prostate Testing for Cancer and Treatment (ProtecT) study in the United Kingdom is a prospective randomized controlled trial evaluating the cost-effectiveness of conventional treatment modalities in PSA-detected clinically localized prostate cancer. Here, KLK3 is linked to cancer.